BACKGROUND: Cholecalciferol (vitamin D3) is widely supplemented in breast cancer survivors because of the role of vitamin D in multiple health outcomes.
Introduction
Cholecalciferol (vitamin D3) is widely supplemented in breast cancer survivors because of the favourable effect of vitamin D on multiple health outcomes, including: maintained bone integrity, muscle strength and immunity; reduced inflammation, cardiovascular disease mortality and cancer risk; and improved mental function, quality of life and survival [1] [2] [3] [4] [5] [6] [7] . Low-to moderate-quality evidence supports an antineoplastic effect of vitamin D with a more favourable prognosis in various cancers, including breast cancer [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Inflammation stress can decrease the levels of 25(OH)D by increasing its conversion to the vitamin D active metabolite 1,25(OH)2D [18] . Hypovitaminosis D decreases the conversion of 25(OH)D to 1,25(OH)2D in postmenopausal women [19] . Long-term therapy with certain drugs, especially cytochrome P450-inducing agents commonly used in patients with cancer can decrease the levels of calcitriol through accelerated cytochrome P450-mediated degradation [20, 21] . Some recreational drugs, including tobacco [22, 23] and alcohol [24] can modify the association between protective vitamin D levels and cancer risk. In addition, significant associations with vitamin D receptor gene (VDR) polymorphisms have been reported for prostate, breast, colorectal and skin cancer [25, 26] , suggesting that vitamin D and/or VDR may modulate the risk of cancer. Therefore patients with breast cancer receiving hormonal therapy, chemotherapy, radiotherapy, immunotherapy or combinations thereof, as well as breast cancer survivors and postmenopausal women in general may benefit from adequate levels of vitamin D. The present observational study aimed to investigate 25(OH)D levels and their determinants in a cohort of breast cancer survivors in eastern Switzerland.
Materials and methods

Study population
The study population consisted of all patients taking part in a cross-sectional study on sociodemographic, lifestyle and health characteristics of Swiss patients with early breast cancer, as reported elsewhere [27] . Consecutive patients from the St Gallen Breast Centre (a tertiary referral centre in eastern Switzerland) were offered study participation. Inclusion criteria were a diagnosis of early (nonmetastatic) breast cancer with preoperative, current or completed postoperative treatment and no evidence of recurrence. The study was reported according to the STROBE guidelines for observational studies and approved by the local Ethics Committee (EKSG-Ethikkommission des Kantons St. Gallen, 08/082) and all participants provided informed consent for use and analyses of baseline characteristics, sociodemographic data, questionnaires and biochemical data in this study.
Data collection
All consenting patients were asked to complete a questionnaire about patient-related and sociodemographic variables including age, education, physical activity, smoking habit, place of residence (rural area vs urban area), comorbidity, use of complementary and alternative medicine and calcium and cholecalciferol intake. Vital parameters including weight, height, body mass index (BMI), bone mineral density (BMD) and body composition were recorded for all patients on the basis of routine procedures. Tumour biological characteristics including age at diagnosis, tumour stage, histology and grade of differentiation, hormone-receptor and HER2 status, antitumor treatment (therapy modalities), menopausal status, and concurrent disease were extracted manually from the records. Cholecalciferol intake and serum concentration of the storage metabolite 25(OH)D and the active metabolite 1,25-dihydroxyvitamin D (1,25(OH) 2 D) were recorded at baseline and during a second (follow-up) visit. High-performance liquid chromatography was used to analyse 25(OH)D, (kit by Chromsystems, Gräflingen, Germany) and 1,25(OH)2D was analysed with a radioimmunassay (IDS, Tyne and Wear, UK). Since our assays did not separate the major circulating vitamin D2 and vitamin D3 metabolites and their respective epimers and isobars [28] , we collectively termed them 25(OH)D and 1,25(OH)2D. Vitamin D deficiency was defined as 25(OH)D ≤50 nmol/l (≤20 ng/l); vitamin D insufficiency was defined as 25(OH)D between 50 and 75 nmol/l (20-30 ng/l), and optimal 25(OH)D levels were defined as between 75 and 100 nmol/l (30-40 ng/l), in accordance with the reference values of our assays and internationally accepted concentration intervals [29] [30] [31] .
At the first visit, there were 133 patients already receiving daily calcium-vitamin D3 supplementation as a chewing tablet, and 3 patients already receiving vitamin D3 (cholecalciferol) supplementation alone. After 25(OH)D analysis, 12 patients showing 25(OH)D deficiency were advised to have a loading intramuscular dose of 300 000 IU cholecalciferol, and all patients with 25(OH)D insufficiency or deficiency were advised to take daily calcium-D3 supplementation (500 mg and 800 IU, respectively) as a chewing tablet. 
Statistical analyses
Results
Patients
Between December 2008 and September 2010, 375 patients were offered participation in the study. Twenty-eight (8%) patients declined participation (unwillingness to participate, linguistic problems) and 5 (1%) patients were excluded from the analysis because they did not fulfil the selection criteria (e.g., no history of breast cancer, metastatic disease) or had withdrawn their consent. The remaining 342 patients completed the enrolment questionnaire. Figure 1 
Factors associated with vitamin D levels
We focused our descriptive analyses on the baseline vitamin D levels for which we had more complete laboratory data, as above stated. fig. 7) .
Factors not associated with vitamin D levels
Age, which has been shown to affect 25(OH)D levels in other studies in elderly people [32] [33] [34] [35] chemotherapy at the time of the first visit were on average younger than the patients who had not had chemotherapy at this time point (p ˂0.001). The patients who were under endocrine therapy at the time of the first visit tended to have higher 25(OH)D levels than the smaller number of patients who were not under endocrine therapy at this time. The few patients who were receiving HER2-directed therapy at the time of the first visit tended to have lower 25(OH)D levels than patients who were not under HER2-directed therapy at this time. However, possibly owing to the low sample sizes and therefore the low statistical power, none of the differences in 25(OH)D and 1,25(OH)2D as related to tumour biology or therapy modality reached statistical significance.
Multiple regression analyses
The multiple regression analyses yielded results similar to the univariate models. The interpretation of regression coefficients as depicted in table 7 is exemplified by the continuous variable age (average 25(OH)D decrease per age year is 0.26) and the categorical variable season (25(OH)D is on average 11.51 higher in spring than in winter). BMI and living in an urban area were significant predictors of 25(OH)D. Season and activity were significant and borderline significant, respectively, when nonsignificant age and BMD were eliminated from the model, so finally the same findings are obtained as in the univariate model (table 7; supplementary tables S1, S2, S3 in appendix 1).
Discussion
In this observational study we described the vitamin D status of 332 breast cancer survivors at baseline and in 230 of them at a follow-up visit a median of 210 days thereafter. The effects of factors known to increase the 25(OH)D serum levels, such as sunlight exposure, place of residence, physical activity and supplementation with cholecalciferol, as well as factors known to reduce the 25(OH)D serum levels such as obesity and chemotherapy [36, 37] , were recorded for our cohort. The main conclusion that cholecalciferol supplementation (or lack thereof) was the single most important factor affecting vitamin D levels in our cohort seems to be quite obvious and could have been reached without this study. However, the study showed that a substantial number of patients have suboptimal 25(OH)D levels in spite of ongoing cholecalciferol supplementation. This suggests that adequate vitamin D supplementation regimens must be tailored to individual characteristics, needs and preferences. Cholecalciferol is generated in the skin from 7-dehydrocholesterol or obtained from the diet. Cholecalciferol undergoes a first hydroxylation step in the liver to yield 25(OH)D, which is a widely measured precursor of the hormonally active metabolite, 1,25(OH) 2D. The activation of 25(OH)D to 1,25(OH)2D occurs through a second hydroxylation step occurring in great part in the kidneys, but also in other tissues including tumours [38] [39] [40] . The half-life of 25(OH)D varies between 2 and 5 weeks, depending on multiple factors such as vitamin D compound, ethnic background, vitamin D binding protein (DBP) genotype, kidney and liver function, disease states, pharmaceutical drugs, and the method used to measure the vitamin D metabolite [41] [42] [43] [44] [45] [46] [47] . The terminal half-life of 1,25(OH)2D is much shorter, ranging from only 5 to 10 hours in healthy subjects [48] . Despite cholecalciferol supplementation, we observed that the proportion of patients with 25(OH)D deficiency or insufficiency remained practically unchanged at about 40%, and the proportion of the patients with sufficient 25(OH)D levels remained at about 60% over time (see fig. 2 ). Factors such as place of residence, physical activity, BMI, supplementation compliance and cholecalciferol dosage may help explain these findings. We have seen that people living in a rural area had higher 25(OH)D levels than people living in an urban area. Also, there were many more rural dwellers (72%) than urban dwellers (28%) in our cohort. Most -if not all -patients changed neither their place of residence, their BMI, nor their physical activity during the observation period. Thus, the constancy of these variables between the baseline and the follow-up visit was associated with stable vitamin D proportions during this period.
In our series of patients, both 25(OH)D and 1,25(OH)2D showed seasonal variation, but this seasonal variation was more pronounced with 1,25(OH)2D. This finding indicates that 25(OH)D levels were not sufficient in a large number of patients in our cohort. The active metabolite 1,25(OH)2D does not generally show any seasonal variation provided that 25(OH)D concentrations are sufficient [49] . The effect of cholecalciferol supplementation was not evenly distributed. Whereas most patients experienced a rise in 25(OH)D following oral supplementation, a few patients receiving even a large cholecalciferol dose of 300 000 IU maintained low levels or did not show an adequate rise of 25(OH)D at the second visit. Of these patients, two even had a decrease of their 25(OH)D levels a couple of months after the high-dose supplementation. Also, a large proportion of patients (round 35 and 30% at the first visit and at follow-up, respectively) showed 25(OH)D levels above optimum. We thereby conclude that adequate cholecalciferol supplementation is important to maintain optimal 25(OH)D levels, but most of our patients did not have adequate cholecalciferol supplementation. Limitations to this conclusion include a lack of adjustments for a number of confounding factors, but use of a multiple regression model means that important confounding factors have been included in the analysis. The cholecalciferol dosing regimen is a very important factor in the success of treatment in clinical trials, a point that is only just becoming apparent. The topic was first raised by B.W Hollis [50] and further explained by Hollis and Wagner (2013) [51] . These concepts have been shown to be accurate in a recent meta-analysis of randomised controlled trials involving vitamin D and infection, where bolus dosing of vitamin D failed and daily dosing was a success [52] . The Australasian expert panel of 2016 [53] concluded that (i) the target serum 25(OH)D concentration should be 50 to 60 nmol/l all the year around, with a conservative upper limit <100 nmol/l; (ii) the dosing interval may need to be <2 months to have a continuous benefit; and (iii) a maintenance dose of 1000 IU/day, or an equivalent dose weekly or monthly, is sufficient for most individuals in Australasia. A similar maintenance dose has been recommended to people living in Europe and North America. The dose effects of cholecalciferol on 25(OH)D levels are depicted in figure 8 , which shows that the usual daily maintenance supplementation with 1000 IU cholecalciferol is not enough to bring any appreciable change in the 25(OH)D levels over time in 25(OH)D-deficient patients. This usual dose regimen is well below the 2000-3000 IU/day required to safely raise serum 25(OH)D to optimal levels and normalise parathyroid hormone (PTH) during the winter season in the northern hemisphere [57] . There is currently no good reason to believe that these recommendations should not apply to Swiss breast cancer survivors.
Strengths and limitations
The observational study was originally planned as a crosssectional study without an interventional-therapeutic part. The original study had some predefined hypotheses, e.g., higher socioeconomic status would be associated with higher vitamin D levels and a higher proportion of our patients would have vitamin D levels lower than the reference laboratory values reported in the literature. The descriptive results of our exploratory analyses are hypothesis-generating for future studies. Strengths of our study include the prospective collection of data and prospective analysis plan and the high compliance of patients (>90%) included in the study, thus avoiding a relevant selection bias. Limitations of this descriptive study include: the lack of normal controls; the lack of some outcome measure related to blood levels of 25(OH)D specifically related to breast cancer patients, as well as PTH, since PTH levels would have been helpful in light of the 1,25(OH)2D levels; the lack of adjustment for confounding factors such as the VDR and DBP genotypes; a possible selection bias in connection with the lack of 25(OH)D measurement during the second (follow up) visit in roughly one third of the patients; and the low numbers of patients in some subgroups of tumour stage, type and therapy. The lack of a reference group in our survey is justified by Sakem et al., who determined the 25(OH)D serum concentrations in 1291 subjectively healthy Swiss men and women, 60 years or older, with high-performance liquid chromatography [58] . The percentage of participants in each of the four 25(OH)D deficiency groups -severely deficient (<10 ng/ml), deficient (10-20 ng/ml), insufficient (21-29 ng/ml) and normal (≥30 ng/ml) -were statistically compared. About 66% of the subjects had insufficient lev- 
Conclusion
Although cholecalciferol is widely supplemented in breast cancer survivors in eastern Switzerland, a remarkable fraction of these patients had serum 25(OH)D below (40%) or above (30%) optimal levels, with only 30% of patients presenting optimal levels. As expected, both 25(OH)D and 1,25(OH)2D levels are higher in patients on cholecalciferol supplementation than in patients without supplementation, but usual supplementation regimens are not adequate to bring 25(OH)D levels to the internationally accepted optimal range for a large proportion of patients.
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Results of multiple linear regression models BMI 
